Thanks, Jason, good morning and thank you for joining us on today's call to review our fourth quarter and full year 2025 results. Last July, we rolled out the Indivior Action Agenda to maximize the ...

Thank you, Jason. After that, we'll provide updates on the significant progress we've made with lonvo-z, which is being developed as a potential one-time treatment for patients with hereditary ...